Drugs Containing Excipient (Inactive Ingredient) BIOTIN

« Back to Dashboard

Generic drugs containing BIOTIN excipient

Company	Ingredient	NDC	Excipient
CellTrans Inc	donislecel	73539-001	BIOTIN
Guangdong Quadrant Ecological Technology Co Ltd	hair growth foam (men)	76986-008	BIOTIN
Guangdong Quadrant Ecological Technology Co Ltd	hair growth foam (women)	76986-009	BIOTIN
GUANGZHOU NODA PHARMACEUTICAL TECHNOLOGY INCORPORATED CO LTD	elevate 5% minoxidil hair liquid	78098-303	BIOTIN
GUANGZHOU NODA PHARMACEUTICAL TECHNOLOGY INCORPORATED CO LTD	elevate 2% minoxidil hair liquid	78098-304	BIOTIN
Guangzhou Jianyuan Biological Technology Co Ltd	minoxidil	81653-001	BIOTIN
Guangzhou Jianyuan Biological TechnologyCoLtd	regenivade hair growth (serum) foam	81653-008	BIOTIN

Biotin Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 8, 2026

Biotin is a specialty vitamin ingredient with stronger economics as an active pharmaceutical or nutraceutical ingredient than as a conventional pharmaceutical excipient. Demand is supported by dietary supplements, fortified foods, cosmetics, animal nutrition, laboratory diagnostics, and limited therapeutic applications. The market has low intellectual-property barriers, significant price competition in commodity grades, and higher margins for validated pharmaceutical-grade material, custom premixes, and regulatory documentation.

What is biotin and how is it used in pharmaceutical formulations?

Biotin, also known as vitamin B7 or vitamin H, is a water-soluble vitamin with the chemical name d-biotin and CAS Registry Number 58-85-5. Its molecular formula is C10H16N2O3 and its molecular weight is 244.31 g/mol.

Biotin is used in several formulation roles:

Application	Commercial role of biotin	Typical product category
Nutritional supplementation	Active vitamin ingredient	Tablets, capsules, gummies, liquids
Pharmaceutical nutrition	Micronutrient component	Multivitamins and parenteral nutrition
Fortified foods and beverages	Nutritional fortificant	Cereals, beverages, nutrition bars
Cosmetics	Hair, skin and nail positioning ingredient	Oral beauty products and topical products
Laboratory diagnostics	Binding reagent or assay component	Immunoassays and research reagents
Animal nutrition	Vitamin additive	Feed premixes and veterinary nutrition
Drug formulation	Minor active or formulation component	Specialized products and investigational formulations

Biotin is not generally an excipient in the same sense as microcrystalline cellulose, lactose, povidone, or magnesium stearate. It has a pharmacological and nutritional function. When present in a product to deliver a vitamin dose, it is usually classified as an active ingredient or nutrient rather than an inactive formulation aid.

The distinction affects regulatory treatment, product labeling, quality specifications, and purchasing decisions.

How large is the biotin pharmaceutical and excipient market?

Public market estimates for biotin are inconsistent because commercial reports combine different categories. Some include dietary supplements, while others include feed additives, cosmetics, laboratory reagents, and pharmaceutical ingredients. No single public source provides a reliable, auditable global figure for pharmaceutical-grade biotin alone.

The market should be analyzed in four segments:

1. Human dietary supplements, which represent the largest demand pool.
2. Food, beverage, and animal nutrition, which consume high volumes but face commodity pricing.
3. Pharmaceutical and clinical nutrition products, which use smaller volumes but require higher quality documentation.
4. Laboratory and specialty applications, which can support premium pricing.

The commercial value of pharmaceutical-grade biotin is therefore driven more by grade, certification, packaging, testing, and supply reliability than by tonnage alone.

What factors determine biotin ingredient revenue?

Supplier revenue depends on:

• Assay and impurity profile.
• Compliance with USP-NF, Ph. Eur., or other applicable standards.
• GMP manufacturing controls.
• Batch traceability and change-control systems.
• Stability data and retest periods.
• Particle size and flow characteristics.
• Low-bioburden or low-endotoxin requirements.
• Packaging and contamination controls.
• Customer qualification status.
• Regulatory support in the United States, Europe, China, Japan, and other markets.

High-volume supplement-grade biotin is exposed to price competition. Pharmaceutical customers are less likely to switch suppliers solely for a small price reduction because qualification, analytical bridging, and regulatory updates create switching costs.

What is driving the financial trajectory for biotin?

Biotin has a positive long-term demand profile but limited pricing power. Revenue growth is likely to come from volume expansion, premium grades, and downstream formulation demand rather than sustained increases in the base chemical price.

Demand drivers

The main demand drivers are:

• Growth in hair, skin, and nail supplements.
• Expansion of gummy and chewable dosage forms.
• Increased use of fortified nutrition products.
• Rising demand for premixes and contract manufacturing.
• Continued use in animal feed and veterinary nutrition.
• Growth in high-dose biotin testing and laboratory reagent markets.
• Greater regulatory preference for documented pharmaceutical supply chains.

Biotin demand also benefits from broad consumer recognition. The ingredient is marketed heavily in beauty supplements, even though clinical evidence for benefits in people without biotin deficiency is limited. The National Institutes of Health states that biotin deficiency is rare and that evidence supporting hair, skin, and nail claims in biotin-replete populations is limited (National Institutes of Health, Office of Dietary Supplements, 2024).

Margin pressure

The base ingredient has several characteristics that limit structural margins:

• The molecule is established and off patent.
• Multiple global suppliers can manufacture it.
• The active is chemically defined and analytically straightforward.
• Supplement manufacturers can qualify alternative sources.
• Demand is sensitive to retail trends and private-label competition.
• Large customers can use annual tenders and volume-based pricing.

Margin expansion is more plausible in pharmaceutical-grade and specialty products than in standard bulk material. Suppliers that provide complete regulatory packages, validated methods, stability support, and geographically redundant supply can capture higher gross margins.

Which companies supply pharmaceutical-grade biotin?

The biotin supply chain includes vitamin manufacturers, specialty chemical producers, pharmaceutical ingredient distributors, and formulation companies. Relevant commercial participants include major vitamin and nutrition suppliers such as DSM-Firmenich, Zhejiang Medicine, and other Asian producers and distributors. Product availability, manufacturing location, and grade status vary by market.

A supplier’s commercial position should be assessed through the following data points:

Supplier characteristic	Financial relevance
Direct manufacturing versus distribution	Determines control over cost and supply
Dedicated pharmaceutical grade	Supports premium pricing
USP-NF or Ph. Eur. compliance	Reduces customer qualification friction
Dual-site manufacturing	Reduces shortage and continuity risk
Regulatory history	Affects approval and audit costs
Custom premix capability	Increases customer retention
Regional inventory	Improves delivery performance
Long-term contracts	Stabilizes revenue and capacity utilization

The market is not controlled by a single innovator company. Buyers generally have access to multiple sources, although the number of fully qualified suppliers is smaller than the number of companies offering catalog or food-grade material.

What is the FDA regulatory status of biotin?

Biotin is regulated differently depending on product category.

Dietary supplements

In the United States, biotin is commonly sold as a dietary supplement under the Federal Food, Drug, and Cosmetic Act. The FDA has established a Daily Value of 30 micrograms for adults and children aged four years and older in nutrition labeling (U.S. Food and Drug Administration, 2024a).

Supplement products may contain doses substantially above the Daily Value. A 5 mg product contains approximately 167 times the Daily Value, while a 10 mg product contains approximately 333 times the Daily Value.

Pharmaceutical products

Biotin can be used as an ingredient in a pharmaceutical or medical nutrition product, but the regulatory requirements depend on the product’s intended use, dosage form, claims, and route of administration. The use of biotin in a product does not by itself establish FDA approval.

For pharmaceutical customers, the relevant documentation normally includes:

• Identity and assay testing.
• Impurity and degradation-product controls.
• Residual-solvent data.
• Microbiological specifications.
• Stability data.
• GMP manufacturing records.
• Supplier qualification documentation.
• Change-control commitments.
• Certificate of analysis procedures.

Laboratory-test interference

High-dose biotin can interfere with certain laboratory tests that use biotin-streptavidin binding systems. The FDA has warned that biotin may produce falsely high or falsely low results, including results affecting cardiac troponin testing and thyroid assays (U.S. Food and Drug Administration, 2019).

This safety issue affects the commercial market in two ways. It supports continued regulatory scrutiny of high-dose products, and it creates labeling and risk-management obligations for manufacturers. It can also affect hospitals, diagnostic companies, and sponsors developing products containing large amounts of biotin.

What are the USP, European, and quality requirements for biotin?

Biotin quality is generally assessed through compendial and customer-specific specifications. Pharmaceutical buyers may require compliance with the United States Pharmacopeia-National Formulary, European Pharmacopoeia, or an internal specification that incorporates compendial methods.

The key controls include:

• Identification.
• Assay.
• Related substances.
• Water content.
• Residual solvents.
• Elemental impurities.
• Microbial limits.
• Particle characteristics.
• Packaging integrity.
• Stability and retest period.

The United States Pharmacopeia-National Formulary provides standards for identity, strength, quality, and purity where a monograph applies. The FDA’s Inactive Ingredient Database can be used to assess precedent for inactive ingredients in approved drug products, but the presence of biotin in a product does not automatically establish approval for every route, dosage form, or strength (U.S. Food and Drug Administration, 2024b).

What patents protect biotin products?

The core biotin molecule is not protected by a meaningful modern composition-of-matter patent estate. Biotin has been known and commercially used for decades. Commercial exclusivity therefore depends on formulation, delivery system, manufacturing process, use claims, branding, regulatory data, or contractual supply arrangements.

Formulation patents

Potentially relevant patent claims may cover:

• Sustained-release tablets.
• Multivitamin combinations.
• Gummy and chewable compositions.
• Liquid formulations.
• Parenteral nutrition mixtures.
• Topical compositions.
• Combination products containing biotin and other vitamins.
• Encapsulation or taste-masking systems.
• Specific particle sizes or stability profiles.

These claims generally protect a particular formulation, not biotin itself. Their commercial value depends on whether the claimed formulation has meaningful market adoption and whether alternative compositions can avoid infringement.

Method-of-use patents

Method claims may address:

• Treatment of biotin deficiency.
• Use in inherited metabolic disorders.
• Use in hair, skin, or nail conditions.
• Use in neurological or metabolic disease.
• Use in laboratory assay systems.

Method-of-use patents face practical limitations in supplement markets because enforcement depends on labeling, promotion, and the specific claim language. A general ingredient listing may not establish infringement of a disease-treatment method claim.

Manufacturing patents

Manufacturing claims may cover:

• Fermentation systems.
• Microbial strains.
• Intermediate compounds.
• Yield-enhancement methods.
• Purification processes.
• Waste reduction.
• Stereochemical control.

Manufacturing know-how can be commercially important even when it is not protected by an enforceable patent. Process control, yield, impurity management, and scale-up experience can produce cost advantages that are difficult to replicate quickly.

How many patents cover biotin, and is Paragraph IV risk material?

There is no commercially significant Orange Book patent estate for biotin as a standalone ingredient. Biotin is not comparable to a recently approved small-molecule drug with listed composition, formulation, and method-of-use patents.

Exclusivity category	Biotin status
Core composition patent	Expired or commercially irrelevant
Orange Book-listed standalone biotin product	No meaningful listing identified
Paragraph IV challenge	Generally not material
Biosimilar risk	Not applicable
Formulation patent risk	Product-specific
Manufacturing patent risk	Supplier- and process-specific
Trade-secret risk	Potentially relevant
Regulatory exclusivity	Product-specific, not ingredient-wide

Paragraph IV litigation normally concerns an Abbreviated New Drug Application challenging patents listed for a reference drug in the FDA Orange Book. Because biotin does not have a significant standalone reference-drug patent estate, Paragraph IV activity is not a central market risk.

Biosimilar risk is also irrelevant. Biotin is a small molecule and vitamin, not a biologic subject to the biosimilar pathway under the Public Health Service Act.

What is the Orange Book status of biotin?

The FDA Orange Book identifies approved drug products and certain patent and exclusivity information. It is not a general registry of all ingredients sold in the United States.

Biotin’s commercial market is primarily composed of dietary supplements, food ingredients, nutrition products, and specialty materials. Those categories do not create Orange Book exclusivity. A formulation containing biotin could theoretically be approved as a drug and receive a product-specific listing, but that would not create ingredient-wide exclusivity for biotin.

This distinction is important for investors and suppliers. The absence of Orange Book protection means that demand is exposed to competitive formulation entry, private-label substitution, and price-based sourcing.

Are licensing deals important in the biotin market?

Licensing is generally less important than supply, distribution, and contract manufacturing arrangements. The market lacks a single proprietary biotin platform comparable to a patented drug-delivery technology.

Commercial agreements are more likely to involve:

• Regional distribution rights.
• Private-label supplement manufacturing.
• Long-term supply contracts.
• Custom premix production.
• Contract testing and packaging.
• Co-development of gummies, liquids, or combination products.
• Technology transfer for manufacturing processes.

The most valuable contractual protections are often minimum-volume commitments, dual-source restrictions, quality agreements, price-adjustment mechanisms, and change-notification obligations.

What generic launch scenarios exist for biotin products?

Generic entry risk is high for any conventional oral product containing biotin. Tablets, capsules, powders, and many simple combination products can often be replicated without access to proprietary technology.

The risk is lower for:

• Complex modified-release products.
• Sterile or parenteral formulations.
• Products requiring specialized bioavailability data.
• Proprietary delivery systems.
• Products supported by clinically differentiated indications.
• Products with strong manufacturing and regulatory barriers.

For a standard biotin tablet, the likely commercial scenario is rapid price competition after launch. For a pharmaceutical-grade ingredient, substitution may take longer because customers must qualify the supplier and establish analytical comparability.

How does biotin compare with other vitamin ingredients?

Ingredient	Main commercial use	Patent strength	Pricing power	Regulatory profile
Biotin	Beauty supplements, nutrition, diagnostics	Low	Low to moderate	Supplement and nutrient-driven
Vitamin D3	Supplements, fortified foods, pharmaceuticals	Low	Low	Broad consumer and clinical use
Vitamin B12	Supplements, injections, fortified foods	Low	Moderate in injectable grades	Strong pharmaceutical precedent
Folic acid	Prenatal, food fortification, supplements	Low	Low	Public-health and fortification relevance
Vitamin K2	Supplements and specialty nutrition	Low to moderate	Moderate	Product and claim dependent
Iron compounds	Supplements and pharmaceuticals	Low	Moderate	Formulation and tolerability matter

Biotin has stronger consumer marketing visibility than many vitamins but weaker clinical differentiation. Its financial performance is therefore more exposed to supplement trends and brand positioning.

What are the geographic dynamics of the biotin market?

Asia is central to production and export supply, particularly for vitamin and nutritional-ingredient manufacturing. North America and Europe are major formulation, branding, regulatory, and end-market regions.

North America

The United States has significant demand from dietary supplements, private-label products, clinical nutrition, and laboratory diagnostics. Regulatory attention to high-dose biotin and test interference is a continuing market factor.

Europe

The European market places greater emphasis on authorized health claims, food-supplement compliance, GMP documentation, and contaminant controls. Claims substantiation can constrain marketing even when ingredient demand remains strong.

Asia-Pacific

Asia-Pacific combines manufacturing capacity with rising domestic demand for supplements, fortified foods, and beauty products. Cost leadership and production scale are important, but export suppliers must meet destination-market documentation and quality requirements.

Emerging markets

Growth in Latin America, the Middle East, and Southeast Asia is linked to expanding pharmacy channels, consumer health spending, and contract manufacturing. Distribution quality and regulatory registration are more important than patent protection in these markets.

How strong is the biotin patent estate?

The biotin patent estate is weak at the ingredient level and potentially moderate at the formulation or process level.

Patent layer	Strength assessment
Biotin molecule	Very weak
Standard oral dosage forms	Weak
Specialized delivery systems	Moderate, depending on claim scope
Manufacturing processes	Variable
Disease-specific methods	Variable and jurisdiction-specific
Brand and trade dress	Potentially strong for established consumer products
Supplier know-how	Potentially important but often trade-secret based

Investors should not value biotin suppliers on the basis of ingredient exclusivity. Competitive value is more likely to come from manufacturing scale, customer qualification, geographic reach, quality systems, and downstream brands.

What is the financial outlook for biotin?

The base-case outlook is steady volume growth with limited commodity pricing power. Revenue growth should be strongest in premium supplement formats, validated pharmaceutical-grade supply, clinical nutrition, and specialized laboratory applications.

Base-case trajectory

• Volume demand: Moderate growth.
• Standard ingredient pricing: Flat to modestly declining.
• Premium pharmaceutical-grade pricing: More stable.
• Supplier concentration: Moderate, with regional exposure.
• Patent-driven margin expansion: Unlikely.
• Regulatory costs: Rising for high-dose and highly documented products.
• Customer switching: Easy for standard grades, harder for qualified pharmaceutical grades.
• Revenue volatility: Higher in consumer supplements than in contracted pharmaceutical supply.

A supplier with only bulk biotin capacity is exposed to price compression. A supplier with compendial grades, redundant manufacturing, validated analytical methods, and formulation services has a more defensible business model.

Key Takeaways

• Biotin is primarily a vitamin active ingredient and nutritional component, not a conventional pharmaceutical excipient.
• The largest demand pool is dietary supplements, while pharmaceutical-grade material supports higher value per unit.
• The core biotin molecule has no meaningful modern patent exclusivity.
• Orange Book, Paragraph IV, and biosimilar risks are generally immaterial at the ingredient level.
• Formulation and manufacturing patents can matter for specialized products but do not protect the commodity market.
• High-dose biotin creates laboratory-test interference concerns and regulatory exposure.
• Standard-grade pricing is likely to remain competitive because multiple suppliers can manufacture the ingredient.
• Long-term supplier value depends on GMP quality, compendial compliance, supply continuity, customer qualification, and downstream formulation capabilities.
• Financial growth is more likely to come from volume and premium services than from patent-protected pricing.

FAQs

Is biotin an excipient or an active ingredient?

Biotin is generally treated as an active vitamin or nutritional ingredient when included to deliver a vitamin dose. It is not normally classified as a functional excipient such as a binder, filler, lubricant, or disintegrant.

Does biotin have an FDA-approved drug exclusivity period?

Biotin does not have ingredient-wide FDA exclusivity. Any exclusivity would be tied to a specific approved drug product, formulation, regulatory pathway, or patent estate.

Can a company file a Paragraph IV challenge against a biotin product?

A Paragraph IV challenge is possible only where an ANDA references a drug product with relevant Orange Book-listed patents. It is generally not a material market pathway for ordinary biotin supplements or standard biotin ingredients.

Why is pharmaceutical-grade biotin more expensive than food-grade biotin?

Pharmaceutical-grade biotin carries higher costs for GMP controls, validated testing, traceability, stability documentation, supplier audits, change control, packaging, and regulatory support.

Does high-dose biotin create commercial liability for manufacturers?

High-dose biotin can interfere with certain laboratory tests. Manufacturers may face labeling, communication, pharmacovigilance, and customer-support obligations, especially when products contain milligram-level doses.

References

1. National Institutes of Health, Office of Dietary Supplements. (2024). Biotin fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/

2. U.S. Food and Drug Administration. (2019). FDA in brief: FDA reminds patients and health care professionals about potential for biotin interference with certain lab tests. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-reminds-patients-and-health-care-professionals-about-potential-biotin-interference

3. U.S. Food and Drug Administration. (2024a). Daily value on the new nutrition and supplement facts labels. https://www.fda.gov/food/new-nutrition-facts-label/daily-value-new-nutrition-and-supplement-facts-labels

4. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

5. U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

6. United States Pharmacopeia. (2024). USP-NF: United States Pharmacopeia and National Formulary. https://www.usp.org/compounding/general-chapter-excipients-compounding-preparations